CASE REPORT
Infective endocarditis caused by Brucella melitensis in an HIV-positive patient
More details
Hide details
1
Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India
Submission date: 2020-03-15
Final revision date: 2020-11-20
Acceptance date: 2020-12-11
Publication date: 2021-06-30
HIV & AIDS Review 2021;20(2):144-146
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Cardiac complications are becoming more critical in patients with human immunodeficiency virus (HIV) infection. The risk of infectious complications in HIV-positive patients has
decreased with the availability of highly active antiretroviral therapy, but remains high in developing
countries, such as India. HIV patients are at increased risk for recurrent bacterial infections due to
acquired immune suppression.
Case presentation:
We describe a case of a 45-year-old HIV-infected male, on antiretroviral therapy
for 4 years, with invasive endocarditis. On admission, his CD4+ count was 274 cells/μl. The patient
was hemodynamically stable on arrival and was in congestive heart failure. Pallor was present with no
peripheral signs of infective endocarditis. 2D echocardiogram revealed vegetations on the tips of anterior and posterior leaflets of the mitral valve, severe mitral regurgitation, and moderate tricuspid
regurgitation. Blood culture was positive for Brucella melitensis. The patient recovered without any
sequel after six weeks of antibiotic therapy (gentamycin intravenously + rifampicin p.o.). The patient
remains under regular follow-up.
Conclusions:
Brucellosis in general is a difficult diagnosis to make. Therefore, along with diagnosis,
treatment is also delayed leading to devastating outcomes. Cardiac involvement occurs in only 2%
of cases but accounts for 80% of mortality due to brucellosis. Brucella endocarditis should be suspected
in HIV patients with endocarditis, who have negative blood cultures and risk of exposure. The most
accepted treatment for B. endocarditis is a combination of anti-microbial therapy with surgery.
REFERENCES (11)
1.
Sousa C, Botelho C, Rodrigues D, et al. Infective endocarditis in intravenous drug abusers: an update. Eur J Clin Microbiol Infect Dis 2012; 9: 2905-2910.
2.
Brown P, Levine D. Infective endocarditis in the injection drug user. Infect Dis Clin North Am 2002; 16: 645-665.
3.
Netzer RO, Zollinger E, Seiler C, et al. Infective endocarditis: clinical spectrum, presentation, and outcome. An analysis of 212 cases, 1980-1995. Heart 2000; 84: 25-30.
4.
Hogevik H, Olaison L, Andersson R, et al. Epidemiologic aspects of infective endocarditis in an urban population: a 5-year prospective study. Medicine 1995; 74: 324-339.
5.
Currie PF, Sutherland GR, Jacob AJ, et al. A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection. Eur Heart J 1995; 16 (Suppl B): 15-18.
6.
Fernández Guerrero ML, Torres Perea R, Gomez Rodrigo J, et al. Infectious endocarditis due to non-Typhi Salmonella in patients infected with human immunodeficiency virus: report of two cases and review. Clin Infect Dis 1996; 22: 853-855.
7.
Nahass RG, Weinstein MP, Bartels J, et al. Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and -positive patients. J Infect Dis 1990; 162: 967-970.
8.
Nel SH, Naidoo DP. An echocardiographic study of infective endocarditis, with special reference to patients with HIV. Cardiovasc.
10.
Kulkarni SK, Bhairappa S, Rangan K. A tale of four valves: outcome of Brucella endocarditis: a case series. Eur Heart J Case Rep 2019; 3: ytz035.
11.
Cafardi JM, Haas D, Lamarre T, Feinberg J. Brucella endocarditis in persons who inject drugs. Open Forum Infect Dis 2020; 7: ofaa063.